Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.08)
# 4,245
Out of 4,876 analysts
4
Total ratings
25%
Success rate
-39.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $23.15 | +293.09% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.10 | +990.91% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $79.10 | +41.59% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $23.15
Upside: +293.09%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.10
Upside: +990.91%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $79.10
Upside: +41.59%